Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)

DRUG2 trials

Sponsors

ViiV Healthcare

Conditions

HIV InfectionsInfection, Human Immunodeficiency Virus

Phase 3

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

CompletedNCT02831764

ViiV HealthcareHIV Infections, Infection, Human Immunodeficiency Virus

Start: 2016-07-18End: 2022-06-29Updated: 2023-12-07

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

CompletedNCT02831673

ViiV HealthcareHIV Infections, Infection, Human Immunodeficiency Virus

Start: 2016-07-21End: 2022-08-15Updated: 2023-08-24

Related Papers

Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT Trials

Open Forum Infectious Diseases2025-02-282 citations

Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies

HIV Research & Clinical Practice2021-12-1611 citations

1024. Impact of Treatment Adherence on Efficacy of DTG/3TC and DTG + TDF/FTC: Pooled Analysis of the GEMINI 1 and 2 Clinical Trials

Open Forum Infectious Diseases2020-10-011 citations

2842. Durable Efficacy of Two-Drug Regimen (2DR) of Dolutegravir (DTG) plus Lamivudine (3TC) in Antiretroviral Treatment-Naïve Adults with HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies

Open Forum Infectious Diseases2019-10-01

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.

2018-11-09272 citations

Dolutegravir–lamivudine as initial therapy in HIV‐1 infected, ARV‐naive patients, 48‐week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study

Journal of the International AIDS Society2017-01-01101 citations